A Cancer Test Approval Meets a High Valuation
Guardant Health, Inc. (NASDAQ:GH) is moving beyond identifying mutations at diagnosis toward testing patients repeatedly as their cancer changes. Recent FDA approval of Guardant360 CDx as a companion diagnostic for AstraZeneca’s camizestrant in advanced breast cancer reinforces that shift. The financial opportunity is not merely another test indication; it is the possibility that repeat molecular monitoring becomes routine clinical practice. But adoption and reimbursement must turn that promise into profitable volume.
In a September 25 CNBC interview, co-CEO Helmy Eltoukhy described using blood tests to detect emerging treatment resistance before it becomes visible on scans. The clinical approach could widen use of liquid biopsy, although the drug’s clinical benefit should not be attributed to the diagnostic test alone. An approved companion diagnostic identifies eligible patients; it does not independently deliver the treatment’s outcome.
Guardant Health, Inc. ranks sixth among the 11 best cancer stocks to invest in now, ranked by Q2 2026 hedge fund holders. Which five oncology names had greater institutional participation, and how do their existing profits compare with Guardant’s investment in testing capacity?
Fast Test Growth Has Not Yet Produced Positive Cash Flow
The business has traction well beyond the new indication. In Q2 2026, revenue increased 44% to $335 million. Oncology revenue climbed 38% to $219.1 million as testing volume rose 63% to approximately 104,000 tests. Shield colorectal screening revenue reached $52.9 million from $14.8 million a year earlier, on roughly 66,000 tests versus 16,000. Screening is expanding more quickly than the company’s ability to make it cash-generative.
The economics explain that tension. Non-GAAP gross margin edged up to 67% from 66%, but operating spending rose as Guardant Health, Inc. expanded sales coverage and laboratory capacity. Adjusted EBITDA loss widened to $55.9 million from $51.9 million, and quarterly free cash flow was negative $69.5 million. Testing more patients is a necessary step toward scale; it is not sufficient proof of operating leverage.
Coverage broadening could change that trajectory. American Cancer Society guideline inclusion and UnitedHealthcare coverage strengthened Shield’s commercial pathway. Guardant raised 2026 screening revenue guidance to $218 million-$230 million and total revenue guidance to $1.34 billion-$1.36 billion. Yet its free cash flow burn forecast also increased to $195 million-$205 million as it accelerates capacity investment. Our comparison of Guardant’s operating model with GRAIL’s shows why reimbursement, margins, and cash consumption matter more than a screening headline.
A Sales Multiple Prices In Several Years of Execution
A traditional earnings multiple is not meaningful while Guardant reports net losses. Its October 19 Seeking Alpha snapshot lists trailing enterprise value to sales at 18.53 times and forward EV/sales at 16.13 times, against sector medians of 3.63 and 3.61 times. Those are demanding multiples for a company still spending more cash than it generates. A premium can be warranted by growth, but profitability must eventually catch up with the valuation.
The same data shows no meaningful P/E through 2027, then illustrative estimated P/Es of 107.58 times for 2028 and 25.38 times for 2029. Consensus EPS growth of 72.05% in 2027 and 323.94% in 2029 reflects a forecast transition from losses to profitability, not an established earnings-growth record. However, those percentage figures warrant particular caution when the underlying earnings base is small or negative.
Guardant Health, Inc. ended June with approximately $1.2 billion in cash, cash equivalents, and restricted cash, while its valuation snapshot separately listed $1.70 billion in total debt. That funding mix raises the cost of delays if new tests require more reimbursement support, clinician adoption or sales spending than planned. The broader debate over whether GRAIL’s screening opportunity justifies its valuation illustrates why early-detection potential alone cannot settle the price question.
The Launch Pace, Not the Approval Alone, Is the Test
On October 12 Morgan Stanley lifted its target to $200 from $185 and maintained Overweight; Barclays raised its target to $220 from $200 on October 7. Both assessments followed a period of rapidly expanding testing use, but targets remain analyst judgments rather than forecasts of clinical adoption.
Insider Monkey tracked 80 hedge funds holding Guardant Health, Inc. in Q2, up from 58 in Q1. Shares sold short rose to 11.92 million on September 30 from 11.05 million in August, equal to 9.25% of float. Importantly, those snapshots predate some October events and cannot establish investor motives.
Looking ahead, the next valuation test is whether recurring monitoring and the Shield screening rollout generate sufficient revenue per test, margin improvement, and cash savings to support profitability.
READ NEXT: Guardant Health’s Screening Growth And Analyst Outlook and Guardant Health’s Expansion Of Shield In Asia.
Hedge Fund Resource Center